D
Douglas G. McNeel
Researcher at University of Wisconsin-Madison
Publications - 179
Citations - 5506
Douglas G. McNeel is an academic researcher from University of Wisconsin-Madison. The author has contributed to research in topics: Prostate cancer & Antigen. The author has an hindex of 41, co-authored 156 publications receiving 4665 citations. Previous affiliations of Douglas G. McNeel include Memorial Sloan Kettering Cancer Center & Wisconsin Alumni Research Foundation.
Papers
More filters
Journal ArticleDOI
Potentiating Endogenous Antitumor Immunity to Prostate Cancer through Combination Immunotherapy with CTLA4 Blockade and GM-CSF
Lawrence Fong,Serena S. Kwek,Shaun O'Brien,Brian D. Kavanagh,Douglas G. McNeel,Vivian Weinberg,Amy M. Lin,Jonathan E. Rosenberg,Charles J. Ryan,Brian I. Rini,Eric J. Small +10 more
TL;DR: Results show that this combination immunotherapy can induce the expansion not only of activated effector CD8 T cells in vivo but also of T cells that are specific for known tumor-associated antigens from the endogenous immune repertoire.
Journal ArticleDOI
Safety and Immunological Efficacy of a DNA Vaccine Encoding Prostatic Acid Phosphatase in Patients With Stage D0 Prostate Cancer
Douglas G. McNeel,Edward J. Dunphy,James G. Davies,Thomas Frye,Laura E. Johnson,Mary Jane Staab,Dorothea Horvath,Jane Straus,Dona Alberti,Rebecca Marnocha,Glenn Liu,Jens C. Eickhoff,George Wilding +12 more
TL;DR: The demonstration that a DNA vaccine encoding PAP is safe, elicits an antigen-specific T-cell response, and may be associated with an increased PSA doubling time suggests that a multi-institutional phase II trial designed to evaluate clinical efficacy is warranted.
Journal ArticleDOI
Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma.
Toni K. Choueiri,Mayer Fishman,Bernard Escudier,David F. McDermott,Charles G. Drake,Harriet M. Kluger,Walter M. Stadler,Jose Luis Perez-Gracia,Douglas G. McNeel,Brendan D. Curti,Michael R. Harrison,Elizabeth R. Plimack,Leonard Joseph Appleman,Lawrence Fong,Laurence Albiges,Lewis J. Cohen,Tina C. Young,Scott D. Chasalow,Petra Ross-Macdonald,Shivani Srivastava,Maria Jure-Kunkel,John F. Kurland,Jason S. Simon,Mario Sznol +23 more
TL;DR: Immunomodulatory effects of PD-1 inhibition were demonstrated through multiple lines of evidence across nivolumab doses in a hypothesis-generating prospective mRCC trial of previously treated patients with metastatic renal cell carcinoma.
Journal ArticleDOI
Pre-existent immunity to the HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian cancer.
TL;DR: It is suggested that patients with advanced stage HER-2/neu overexpressing breast and ovarian cancer can mount a T cell and/or antibody immune response to their tumor.
Journal ArticleDOI
Phase I Trial of a Monoclonal Antibody Specific for αvβ3 Integrin (MEDI-522) in Patients with Advanced Malignancies, Including an Assessment of Effect on Tumor Perfusion
Douglas G. McNeel,Jens C. Eickhoff,Fred T. Lee,David M. King,Dona Alberti,James P. Thomas,Andreas Friedl,Jill M. Kolesar,Rebecca Marnocha,Jennifer Volkman,Jianliang Zhang,Luz Hammershaimb,James A. Zwiebel,George Wilding +13 more
TL;DR: The current phase I dose escalation study evaluated the safety and effectiveness of MEDI-522, a monoclonal antibody specific for the αvβ3 integrin, in patients with advanced malignancies and suggested it could be further investigated as an antiangiogenic agent for the treatment of cancer.